araag2/HINT huggingface dataset:
Clinical trial NCT00599716 (phase 3, status: completed)
Conditions: dry eye disease
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: sodium hyaluronate, vehicle
SMILES: CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adults aged 18 years and over.

          -  Subjects should have at least a 3-month documented history of dry eye in both eyes
             diagnosed as dry eye syndrome, keratoconjunctivitis sicca (KCS), or due to Sjögren
             syndrome (immune exocrinopathy).

          -  Subjects must agree to discontinue all artificial tears from Screening through the
             duration of the treatment period (Screening to Day 14).

          -  Subjects who have taken Restasis® are eligible for inclusion if they have not used
             Restasis® during the 4 weeks prior to Screening.

          -  Subjects must discontinue lens wear one week before Screening and agree not to wear
             contact lenses during the entire study.

          -  Subjects must provide signed informed consent prior to participation in any
             study-related procedures.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Females of childbearing potential who are not using systemic contraception, are not
             postmenopausal (≥ 1 year), or are not surgically sterilized.

          -  Ocular surgery (of any type, including laser surgery) or ocular trauma within the 4
             months prior to Screening.

          -  Other diseases or characteristics judged by the investigator to be incompatible with
             the assessments needed in this study or with reliable instillation of the study
             medication.

          -  Any active inflammation of the eye not due to KCS (eg, iritis, scleritis, etc.).

          -  Participation in any other clinical trial within 30 days prior to Screening.

          -  Prior participation in a previous clinical trial of Vismed®.
Clinical trial NCT00374777 (phase 3, status: completed)
Conditions: sleep initiation and maintenance disorders
ICD codes: Y93.E9, Y93.H9
Drugs: zolpidem mr, nitrazepam, placebo
SMILES: CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, [O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Nonorganic insomnia associated with schizophrenia and manic-depressive psychosis.

        Exclusion Criteria:

          -  Patients with allergic reactions to zolpidem or nitrazepam; Patients with serious
             cardiac disorders; serious hepatic impairment; serious renal diseases.
Clinical trial NCT00200681 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: velcade
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Recently diagnosed MM according to the criteria of the South West Oncology Group
             (SWOG)

          -  Not previously treated, apart from local radiotherapy, in the case of a threatening or
             incapacitating lesion, and/or a 4-day block of dexamethasone (40 mg/mL) in an
             emergency

          -  Stage II or III disease according to the Durie and Salmon classification or Stage I
             disease with symptomatic bone lesion

          -  < 65 years of age

          -  Ability to give signed informed consent

          -  Secretion of a measurable monoclonal spike (> 10 g/l in the serum or 0.2 g/24h in the
             urine)

          -  Negative pregnancy test at inclusion (if necessary)

          -  Absence of active infection. In the case of infection, appropriate antibiotic therapy
             must be administered and patients must have been apyretic for 48 hours before the
             start of treatment with VAD or Velcade®/dexamethasone

        Exclusion Criteria:

          -  ECOG performance status > 2

          -  History of cancer (other than basal cell carcinoma or carcinoma of the cervix in situ)

          -  Life expectancy < 2 months

          -  Confirmed amyloidosis

          -  Positive HIV serology

          -  Serious psychiatric item in the history

          -  Renal failure requiring dialysis

          -  Uncontrolled diabetes, contra-indicating the use of corticosteroids

          -  Peripheral neuropathy National Cancer Institute (NCI) grade > 2 (Annex 5)

          -  Clinical signs of heart failure or coronary heart disease

          -  Bilirubin > 3 x normal

          -  Transaminases or gamma-glutamyl transpeptidase (GT) > 4 x normal

          -  Platelets < 50 x 10^9/l during the 15 days prior to inclusion

          -  Neutrophils < 0.75 x 10^9/l during the 15 days prior to inclusion

          -  Use of an investigational medicinal product during the 30 days prior to inclusion

          -  Known hypersensitivity to bortezomib, boron or mannitol
Clinical trial NCT00437476 (phase 3, status: unknown status)
Conditions: hiv infections, hepatitis c
ICD codes: Z21, B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: lpv/r, nucleoside reverse transcriptase inhibitors, peg-ifna 2a, ribavirin
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is >18 years old

          -  Subject has given written informed consent

          -  Serologic evidence of HIV infection by HIV antibody and HIV-RNA detection

          -  Serologic evidence of HCV infection by HCV antibody and HCV-RNA detection

          -  Subject is naive for HIV and HCV therapy

          -  Subject has active chronic hepatitis or compensated cirrhosis (Child-Pugh class A)

          -  Subject has a CD4+ count > 200 cell/mm3 and <500 cell/mm3.

          -  Subject has genotype available at baseline and no mutations (IAS)associated with
             resistance to antiretroviral drugs used.

          -  Subject and partner will use effective contraceptive methods for the duration of the
             study

        Exclusion Criteria:

          -  Subject is HbsAg positive

          -  Subject has cirrhosis score Child-Pugh B/C, no previous hepatic decompensation

          -  Subject has HIV-related thrombocytopenia (Platelets count < 50.000 mmc)

          -  Subject has neutrophils count < 1500/mmc

          -  Subject has Hb value < 9 g/dL at screening and <11 g/dL at randomization

          -  Subject has creatinine value > 1.5 mg/dL

          -  Subject is on a HAART regimen included ddI and/or AZT

          -  Subject is pregnant or wishes to become so

          -  Subject has any cause of liver disease other than chronic hepatitis C, status of liver
             decompensation or any other condition consistent with decompensated liver disease
             (bleeding from esophageal varices, signs of current bleeding, significant ascites,
             hepatic encephalopathy)

          -  Subject is alcohol abuser (> 30 gr/die)

          -  Prior treatment with PEG-IFN/ribavirin

          -  Illicit drugs abuse that in the opinion of the investigator could lead to poor
             compliance with the terms of the protocol (maintenance treatment with methadone
             allowed)

          -  Active heart disease (e.g. angina, congestive heart failure, recent myocardial
             infarction, or significant arrhythmia)

          -  Subject has pre-existing severe depression, condition of severe psychiatric disorders
             such as suicidal ideation, suicide attempts, depression or acute psychosis
Clinical trial NCT00120900 (phase 3, status: completed)
Conditions: osteoarthritis, knee
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: gw406381
SMILES: CCOC1=CC=C(C=C1)C1=NN2N=CC=CC2=C1C1=CC=C(C=C1)S(C)(=O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Subjects have a primary diagnosis of osteoarthritis of the knee with symptom duration
             of at least 3 months.

          -  Use pain medication, such as a COX-2 inhibitor or NSAID (non-steroidal
             anti-inflammatory drug) at least 5 days per week.

        Exclusion criteria:

          -  History of hypersensitivity or intolerance to pain medications.

          -  History of gastroduodenal perforations and/or obstructions.

          -  History of upper GI (gastrointestinal) ulceration within the previous 6 months.

          -  History of upper or lower GI bleeding within the previous year.

          -  History of inflammatory bowel disease.

          -  Currently take sucralfate or misoprostol.

          -  Currently taking aspirin daily for the heart.

          -  Other restrictions around the use medications apply and would need to be discussed.

          -  History of coronary artery disease, (angina, MI) or surgery.

          -  History of congestive heart failure or renal artery stenosis.

          -  History of stroke or transient ischemic attack.

          -  History of uncontrolled hypertension.
Clinical trial NCT01767116 (phase 3, status: completed)
Conditions: chronic hepatitis c infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-450/r/abt-267, abt-333, ribavirin, placebo for ribavirin
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females must be practicing specific forms of birth control on study treatment, or be
             post-menopausal for more than 2 years or surgically sterile

          -  Chronic hepatitis C, genotype 1b-infection (HCV RNA level greater than or equal to
             10,000 IU/mL at screening)

          -  Subject has never received antiviral treatment for hepatitis C infection

          -  No evidence of liver cirrhosis

        Exclusion Criteria:

          -  Significant liver disease with any cause other than HCV as the primary cause

          -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody

          -  Positive screen for drugs or alcohol

          -  Significant sensitivity to any drug

          -  Use of contraindicated medications within 2 weeks of dosing

          -  Abnormal laboratory tests
Clinical trial NCT00122382 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, placebo, methotrexate
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis (RA) <=2 years; MTX naive or <=10 mg/wk for <=3
             weeks. No dose within 3 months prior to informed consent.

          -  C-Reactive Protein (CRP) >= 4.5 mg/L (after amendment)

          -  Rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP) positive

          -  Tender joints >=12 and swollen joints >=10

        Exclusion Criteria:

          -  Women and men who are not willing to use birth control

          -  Diagnosed with other rheumatic disease

          -  History of cancer within 5 years

          -  Active tuberculosis

          -  Treatment with another investigation drug within 28 days

          -  Active bacterial or viral infection
Clinical trial NCT00031863 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: rofecoxib
SMILES: CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal carcinoma

               -  Stage II (T3-4, N0, M0) or stage III (any T, N1-2, M0) disease

          -  Completely resected primary tumor without gross or microscopic evidence of residual
             disease

          -  Must have received potentially curative therapy within the past 12 weeks, including
             any of the following:

               -  Surgery alone

               -  Surgery plus radiotherapy and/or chemotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  WHO 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST/ALT no greater than 1.5 times ULN

        Renal:

          -  Creatinine clearance greater than 30 mL/min

        Cardiovascular:

          -  No severe congestive heart failure

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No active peptic ulcer or gastrointestinal bleeding within the past year

          -  No inflammatory bowel disease

          -  No known sensitivity to rofecoxib

          -  No prior adverse reaction to non-steroidal anti-inflammatory drugs (NSAIDs) (e.g.,
             asthma, acute rhinitis, nasal polyps, angioneurotic edema, or urticaria)

          -  No other malignancy within the past 10 years except adequately treated carcinoma in
             situ of the cervix or basal cell or squamous cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No concurrent long-term NSAIDs except low-dose aspirin (no more than 80 mg/day) for
             cardio-prophylaxis
Clinical trial NCT00168298 (phase 3, status: completed)
Conditions: macular edema, retinal vein occlusion
ICD codes: H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120, H34.8131, H34.8132, H34.8111, H34.8121, H34.8191, H34.8331, H34.8112
Drugs: 700 µg dexamethasone, 350 µg dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Key Inclusion Criteria:

          -  18 years of age or older with macular edema resulting from retinal vein occlusion

          -  Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or
             worse)

          -  Visual acuity in other eye no worse than 20/200

        Key Exclusion Criteria:

          -  Known anticipated need for ocular surgery within next 12 months

          -  History of glaucoma or current high eye pressure requiring more than 1 medication

          -  Diabetic retinopathy

          -  Uncontrolled systemic disease

          -  Known steroid-responder

          -  Use of systemic steroids

          -  Use of warfarin/heparin
Clinical trial NCT00615264 (phase 3, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: diapep277, placebo
SMILES: [H][C@](C)(O)[C@]([H])(N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(CO)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(C)N=C(O)[C@]1([H])CCCN1C(=O)[C@@]([H])(N=C(O)[C@@]([H])(N=C(O)[C@]([H])(CCCNC(N)=N)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(C)N=C(O)[C@@]([H])(N=C(O)CN=C(O)CN=C(O)CN=C(O)[C@]([H])(CC(C)C)N=C(O)[C@@]([H])(N)C(C)C)C(C)C)C(C)C)[C@@]([H])(C)CC)C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of type 1 diabetes for up to 3 months at screening

          -  Insulin dependency

          -  Fasting C-peptide levels >= 0.22 nmol/L

          -  Presence of at least 1 of the diabetes-related autoantibodies (IA-2A, GAD or IA)

        Exclusion Criteria:

          -  Pregnancy or intent to conceive in the next 2 years

          -  Significant diseases that could affect response to treatment, such as tumors,
             psychiatric disorders, substance abuse, severe allergies or diabetes-related
             complications.

          -  Patient has immune deficiency or receives immuno-suppressive or cytotoxic drugs.
Clinical trial NCT00076115 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Current primary diagnosis of bipolar I disorder, mania or mixed type

          -  Aged between 10 and 17 years

          -  Young Mania Rating Scale score greater than or equal to 20 at screening and baseline

        Exclusion Criteria:

          -  Known or suspected history of substance dependence

          -  Significant risk for suicidal or violent behavior

          -  Received electroconvulsive treatment within 4 weeks of baseline

          -  Received a depot antipsychotic within 2 treatment cycle before baseline

          -  Is unable to swallow medication taken in the form of tablets

          -  Has a positive result for a urine drug screen done at baseline

          -  Known or suspected seizure disorder

          -  Hypothyroidism or hyperthyroidism, unless stabilized on appropriate medication for at
             least 3 months before screening

          -  Known or suspected history of hypersensitivity or intolerance to risperidone

          -  History of a poor antimanic response to risperidone when used in adequate doses for an
             adequate period as the sole antimanic agent
Clinical trial NCT00309738 (phase 3, status: completed)
Conditions: hypercholesterolemia, dyslipidemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: pitavastatin, simvastatin
SMILES: O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females (18-75 years of age)

          -  At least two cardiovascular disease risk factors

          -  Must have been following a restrictive diet

          -  Diagnosis of primary hypercholesterolemia or combined dyslipidemia

        Exclusion Criteria:

          -  Homozygous familial hypercholesterolemia

          -  Conditions which may cause secondary dyslipidemia

          -  Uncontrolled diabetes mellitus

          -  Abnormal pancreatic, liver or renal function

          -  Abnormal serum creatine kinase (CK) above the pre-specified level
Clinical trial NCT00421928 (phase 3, status: completed)
Conditions: osteoarthritis, knee, pain
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: oxycodone, placebo, tapentadol (cg5503)
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with osteoarthritis of the knee based on the American College of
             Rheumatology (ACR) criteria and functional capacity class of I-III

          -  patients taking analgesic medications for at least 3 months prior to screening and/or
             dissatisfied with their current therapy

          -  Patients requiring opioid treatment must be taking daily doses of opioid-based
             analgesic, equivalent to <160 mg of oral morphine

          -  baseline score of greater than or equal to 5 on an 11-point numerical rating scale,
             calculated as the average pain intensity during the last 3 days prior to
             randomization.

        Exclusion Criteria:

          -  History of alcohol and/or drug abuse in Investigator's judgement

          -  history of significant liver insufficiency

          -  chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past
             3 months

          -  life-long history of seizure disorder or epilepsy

          -  history of malignancy within past 2 years, with exception of basal cell carcinoma that
             has been successfully treated

          -  uncontrolled hypertension

          -  patients with severely impaired renal function

          -  patients with moderate to severly impaired hepatic function or with laboratory values
             reflecting inadequate hepatic function
Clinical trial NCT00369941 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: mk-0518, comparator: efavirenz, comparator: truvada, comparator: placebo to mk-0518, comparator: placebo to efavirenz
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Participant is a male or female at least 18 years of age

          -  Participant is HIV positive

          -  Participant is naïve to antiretroviral therapy (ART) and has not received any ART

        Exclusion Criteria:

          -  Participant has received approved or experimental antiretroviral agents in the past

          -  Participant has been treated for a viral infection other than HIV such as hepatitis B
             virus infection with an agent that is active against HIV including but not limited to
             adefovir or lamivudine (= 7 days total)

          -  Participant has documented resistance to tenofovir, emtricitabine, and/or efavirenz

          -  Participant has used another experimental HIV-integrase inhibitor

          -  Participant has a current (active) diagnosis of acute hepatitis due to any cause

          -  Participants with chronic hepatitis including chronic hepatitis B and/or C may enter
             the study as long as they have stable liver function tests